Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Human Papillomavirus | Research article

Association of cervical carcinogenesis risk with HPV16 E6 and E7 variants in the Taizhou area, China

Authors: Mei-Zhen Dai, Yi Qiu, Xing-Hong Di, Wei-Wu Shi, Hui-Hui Xu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Human papillomavirus (HPV) type 16 accounts for a larger share of cervical cancer and has been a major health problem worldwide for decades. The progression of initial infection to cervical cancer has been linked to viral sequence properties; however, the role of HPV16 variants in the risk of cervical carcinogenesis, especially with longitudinal follow-up, is not fully understood in China.

Methods

We aimed to investigate the genetic variability of HPV16 E6 and E7 oncogenes in isolates from cervical exfoliated cells. Between December 2012 and December 2014, a total of 310 single HPV16-positive samples were selected from women living in the Taizhou area, China. Sequences of all E6 and E7 oncogenes were analysed by PCR-sequencing assay. Detailed sequence comparison, genetic heterogeneity analyses and maximum-likelihood phylogenetic tree construction were performed with BioEdit Sequence Alignment Editor and MEGA X software. Data for cytology tests and histological diagnoses were obtained from our Taizhou Area Study with longitudinal follow-up for at least 5 years. The relationship between HPV16 variants and cervical carcinogenesis risk was analysed by the chi-square test or Fisher’s exact test.

Results

In this study, we obtained 64 distinct variation patterns with the accession GenBank numbers MT681266-MT681329. Phylogenetic analysis revealed that 98.3% of HPV16 variants belong to lineage A, in which the A4 (Asian) sublineage was dominant (64.8%), followed by A2 (12.1%), A1 (11.4%), and A3 (10.0%). The A4 (Asian) sublineage had a higher risk of CIN2+ than the A1–3 (European) sublineages (OR = 2.69, 95% CI = 1.04–6.97, P < 0.05). Furthermore, nucleotide variation in HPV16 E6 T178G is associated with the development of cervical cancer.

Conclusion

These data could provide novel insights into the role of HPV16 variants in cervical carcinogenesis risk in China.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–82. https://doi.org/10.1016/S0140-6736(18)32470-X.CrossRefPubMed

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.CrossRef

de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1–2):2–10. https://doi.org/10.1016/j.virol.2013.04.023.CrossRefPubMed

Alejo M, Alemany L, Clavero O, Quiros B, Vighi S, Seoud M, et al. Contribution of human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases. Papillomavirus Res. 2018;5:134–42. https://doi.org/10.1016/j.pvr.2018.03.005.CrossRefPubMedPubMedCentral

Xu HH, Wang K, Feng XJ, Dong SS, Lin A, Zheng LZ, et al. Prevalence of human papillomavirus genotypes and relative risk of cervical cancer in China: a systematic review and meta-analysis. Oncotarget. 2018;9(20):15386–97. https://doi.org/10.18632/oncotarget.24169.CrossRefPubMedPubMedCentral

Xu H, Lin A, Shao X, Shi W, Zhang Y, Yan W. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China. Oncotarget. 2016;7(50):83775–83. https://doi.org/10.18632/oncotarget.11959.CrossRefPubMedPubMedCentral

Xu HH, Lin A, Chen YH, Dong SS, Shi WW, Yu JZ, et al. Prevalence characteristics of cervical human papillomavirus (HPV) genotypes in the Taizhou area, China: a cross-sectional study of 37967 women from the general population. BMJ Open. 2017;7(6):e014135. https://doi.org/10.1136/bmjopen-2016-014135.CrossRefPubMedPubMedCentral

Kukimoto I, Muramatsu M. Genetic variations of human papillomavirus type 16: implications for cervical carcinogenesis. Jpn J Infect Dis. 2015;68(3):169–75. https://doi.org/10.7883/yoken.JJID.2014.584.CrossRefPubMed

10.

Rader JS, Tsaih SW, Fullin D, Murray MW, Iden M, Zimmermann MT, et al. Genetic variations in human papillomavirus and cervical cancer outcomes. Int J Cancer. 2019;144(9):2206–14. https://doi.org/10.1002/ijc.32038.CrossRefPubMedPubMedCentral

11.

van der Weele P, Meijer CJLM, King AJ. Whole-Genome Sequencing and Variant Analysis of Human Papillomavirus 16 Infections. J Virol. 2017; 91(19): pii: e00844–e00817.

12.

Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol. 2018;26(2):158–68. https://doi.org/10.1016/j.tim.2017.07.007.CrossRefPubMed

13.

Mirabello I, Clarke MA, Nelson CW, Dean M, Wentzensen N, Yeager M, et al. The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis. Viruses. 2018;10(2):80.CrossRef

14.

Clifford GM, Tenet V, Georges D, Alemany L, Pavón MA, Chen Z, et al. Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Res. 2019;7:67–74. https://doi.org/10.1016/j.pvr.2019.02.001.CrossRefPubMedPubMedCentral

15.

Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445(1–2):232–43. https://doi.org/10.1016/j.virol.2013.07.018.CrossRefPubMed

16.

Mirabello L, Yeager M, Cullen M, Boland JF, Chen Z, Wentzensen N, et al. HPV16 sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200 women. J Natl Cancer Inst. 2016;108(9):djw100.CrossRef

17.

Cornet I, Gheit T, Clifford GM, Combes JD, Dalstein V, Franceschi S, et al. Human papillomavirus type 16 E6 variants in France and risk of viral persistence. Infect Agent Cancer. 2013;8(1):4. https://doi.org/10.1186/1750-9378-8-4.CrossRefPubMedPubMedCentral

18.

Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35(6):1547–9. https://doi.org/10.1093/molbev/msy096.CrossRefPubMedPubMedCentral

19.

Galati L, Equestre M, Bruni R, Accardi L, Torti C, Fiorillo MT, et al. Identification of human papillomavirus type 16 variants circulating in the Calabria region by sequencing and phylogenetic analysis of HPV16 from cervical smears. Infect Genet Evol. 2019;68:185–93. https://doi.org/10.1016/j.meegid.2018.12.024.CrossRefPubMed

20.

Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16(3):175–204.CrossRef

21.

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.CrossRef

22.

Chen Z, DeSalle R, Schiffman M, Herrero R, Wood CE, Ruiz JC, et al. Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. PLoS Pathog. 2018;14(11):e1007352. https://doi.org/10.1371/journal.ppat.1007352.CrossRefPubMedPubMedCentral

23.

Pimenoff VN, de Oliveira CM, Bravo IG. Transmission between archaic and modern human ancestors during the evolution of the oncogenic human papillomavirus 16. Mol Biol Evol. 2017;34(1):4–19. https://doi.org/10.1093/molbev/msw214.CrossRefPubMed

24.

Freitas LB, Chen Z, Muqui EF, Boldrini NA, Miranda AE, Spano LC, et al. Human papillomavirus 16 non-European variants are preferentially associated with high-grade cervical lesions. PLoS One. 2014;9(7):e100746. https://doi.org/10.1371/journal.pone.0100746.CrossRefPubMedPubMedCentral

25.

Hang D, Yin Y, Han J, Jiang J, Ma H, Xie S, et al. Analysis of human papillomavirus 16 variants and risk for cervical cancer in Chinese population. Virology. 2016;488:156–61. https://doi.org/10.1016/j.virol.2015.11.016.CrossRefPubMed

26.

Liu Y, Pan Y, Gao W, Ke Y, Lu Z. Whole-genome analysis of human papillomavirus types 16, 18, and 58 isolated from cervical Precancer and Cancer samples in Chinese women. Sci Rep. 2017;7(1):263. https://doi.org/10.1038/s41598-017-00364-9.CrossRefPubMedPubMedCentral

27.

Zhao J, Zhu J, Guo J, Zhu T, Zhong J, Liu M, et al. Genetic variability and functional implication of HPV16 from cervical intraepithelial neoplasia in Shanghai women. J Med Virol. 2020;92(3):372–81. https://doi.org/10.1002/jmv.25618.CrossRefPubMed

28.

Zhou Z, Yang H, Yang L, Yao Y, Dai S, Shi L, et al. Human papillomavirus type 16 E6 and E7 gene variations associated with cervical cancer in a Han Chinese population. Infect Genet Evol. 2019;73:13–20. https://doi.org/10.1016/j.meegid.2019.04.008.CrossRefPubMed

29.

Cao M, Chenzhang Y, Ding X, Zhang Y, Jing Y, Chen Z. Genetic variability and lineage phylogeny of human papillomavirus type-16 and -53 based on the E6, E7, and L1 genes in Southwest China. Gene. 2016;592(1):49–59. https://doi.org/10.1016/j.gene.2016.07.039.CrossRefPubMed

30.

He H, Li H, Fan P, Zhu J, Pan Z, Pan H, et al. Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang. China Infect Agent Cancer. 2016;11(1):44. https://doi.org/10.1186/s13027-016-0089-2.CrossRefPubMed

31.

Zhe X, Xin H, Pan Z, Jin F, Zheng W, Li H, et al. Genetic variations in E6, E7 and the long control region of human papillomavirus type 16 among patients with cervical lesions in Xinjiang. China Cancer Cell Int. 2019;19(1):65. https://doi.org/10.1186/s12935-019-0774-5.CrossRefPubMed

32.

Choi BS, Kim SS, Yun H, Jang DH, Lee JS. Distinctive distribution of HPV16 E6 D25E and E7 N29S intratypic Asian variants in Korean commercial sex workers. J Med Virol. 2007;79(4):426–30. https://doi.org/10.1002/jmv.20826.CrossRefPubMed

33.

Chopjitt P, Ekalaksananan T, Pientong C, Kongyingyoes B, Kleebkaow P, Charoensri N. Prevalence of human papillomavirus type 16 and its variants in abnormal squamous cervical cells in Northeast Thailand. Int J Infect Dis. 2009;13(3):212–9. https://doi.org/10.1016/j.ijid.2008.06.017.CrossRefPubMed

34.

Ding T, Wang X, Ye F, Cheng X, Lu W, Xie X. Distribution of human papillomavirus 16 E6/E7 variants in cervical cancer and intraepithelial neoplasia in Chinese women. Int J Gynecol Cancer. 2010;20(8):1391–8. https://doi.org/10.1111/IGC.0b013e3181eced04.CrossRefPubMed

35.

Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett. 2000;156(2):159–65. https://doi.org/10.1016/S0304-3835(00)00457-2.CrossRefPubMed

36.

Chansaenroj J, Theamboonlers A, Junyangdikul P, Swangvaree S, Karalak A, Poovorawan Y. Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pacific J Cancer Prev. 2012;13(2):599–606. https://doi.org/10.7314/APJCP.2012.13.2.599.CrossRef

37.

Jenison SA, Yu XP, Valentine JM, Galloway DA. Characterization of human antibody-reactive epitopes encoded by human papillomavirus types 16 and 18. J Virol. 1991;65(3):1208–18. https://doi.org/10.1128/jvi.65.3.1208-1218.1991.CrossRefPubMedPubMedCentral

38.

Andersson S, Alemi M, Rylander E, Strand A, Larsson B, Sallstrom J, et al. Uneven distribution of HPV 16 E6 prototype and variant (L83V) oncoprotein in cervical neoplastic lesions. Br J Cancer. 2000;83(3):307–10. https://doi.org/10.1054/bjoc.2000.1247.CrossRefPubMedPubMedCentral

39.

Grodzki M, Besson G, Clavel C, Arslan A, Franceschi S, Birembaut P, et al. Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol Biomark Prev. 2006;15(4):820–2. https://doi.org/10.1158/1055-9965.EPI-05-0864.CrossRef

40.

Pande S, Jain N, Prusty BK, Bhambhani S, Gupta S, Sharma R, et al. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in North India. J Clin Microbiol. 2008;46(3):1060–6. https://doi.org/10.1128/JCM.02202-07.CrossRefPubMedPubMedCentral

41.

Cornet I, Gheit T, Iannacone MR, Vignat J, Sylla BS, Del Mistro A, et al. HPV16 genetic variation and the development of cervical cancer worldwide. Br J Cancer. 2013;108(1):240–4. https://doi.org/10.1038/bjc.2012.508.CrossRefPubMed

42.

van der Weele P, King AJ, Meijer CJLM, Steenbergen RDM. HPV16 variant analysis in primary and recurrent CIN2/3 lesions demonstrates presence of the same consensus variant. Papillomavirus Res. 2019;7:168–72. https://doi.org/10.1016/j.pvr.2019.04.008.CrossRefPubMedPubMedCentral

Title: Association of cervical carcinogenesis risk with HPV16 E6 and E7 variants in the Taizhou area, China
Authors: Mei-Zhen Dai
Yi Qiu
Xing-Hong Di
Wei-Wu Shi
Hui-Hui Xu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Human Papillomavirus
Cervical Cancer
Cervical Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08531-y

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Association between preoperative serum albumin and prognosis in patients with adrenocortical carcinoma after primary resection: a retrospective study

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study

Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review

Silencing of FTX suppresses pancreatic cancer cell proliferation and invasion by upregulating miR-513b-5p

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer